Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical-controlled, multicenter, double-blind study

Grants

Funding Acknowledgements

This study was funded by UCB Pharma. The authors acknowledge Jonathon Gibbs (Evidence Scientific Solutions, Horsham, United Kingdom) for writing assistance, which was funded by UCB Pharma, and Jesse Fishman, PharmD, (UCB Pharma, Smyrna, GA, U. S. A.) for manuscript coordination. The authors also acknowledge Svetlana Dimova (UCB Pharma, Brussels, Belgium), Marc De Backer (UCB Pharma, Brussels, Belgium), Tyler Story, PhD (UCB Pharma, Smyrna, GA, U. S. A.), and Konrad Werhahn (UCB Pharma, Monheim am Rhein, Germany) for their editorial suggestions in the development of the manuscript. The authors thank the ALEX-MT Study Group.